Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,[3][4][5][6] but was never marketed.[7]
Clinical data | |
---|---|
Other names | MDL-72,974A |
Routes of administration | Oral[1] |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1–3 hours[1] |
Excretion | Urine[2] |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C11H13F2N |
Molar mass | 197.229 g·mol−1 |
3D model (JSmol) |
|
| |
|